Saturday, April 11, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Breaking News

Pactiv Evergreen Q4 Financial Results Revenue Decline but Positive Outlook with Restructuring Plan

Elaine Mendonca by Elaine Mendonca
March 2, 2024
in Breaking News
0
0
SHARES
12
VIEWS
Share on FacebookShare on Twitter

Pactiv Evergreen shares are on the decline following the release of their Q4 financial results on March 2, 2024.
Revenue dropped by 14% to $1.27 billion, falling short of analyst expectations.
However, adjusted EBITDA saw an improvement from $167 million to $207 million, and adjusted earnings per share rose from $0.17 to $0.33, surpassing estimates.
Pactiv Evergreen also unveiled a restructuring plan aimed at optimizing their footprint, with anticipated cost savings of $35 million by 2026 but restructuring charges of $70 million to $105 million.
The CEO highlighted the company’s progress in 2023 and outlined plans for strategic transformation in 2024 through the footprint optimization plan.
With a price-to-earnings ratio of 14, the stock is considered reasonably priced, especially with potential positive results from cost-cutting initiatives.

PTVE Stock Price Drops 10% on March 2nd – Potential Buying Opportunity for Investors

On March 2, 2024, PTVE stock experienced a significant drop in price, closing at $13.26, which was a decrease of $1.49 from the previous market close. This represented a 10.10% drop in value for the day. However, after-hours trading saw a slight recovery, with the stock rising $0.24.

Investors may be keeping a close eye on PTVE to see if the after-hours trading uptick continues into the next trading day. The stock’s performance on March 2nd could be seen as a buying opportunity for some investors looking to capitalize on the potential for a rebound in price.

PTVE Stock Performance Analysis: Revenue, Net Income, and EPS Decline in 2024

On March 2, 2024, PTVE stock experienced a mixed performance based on the financial data provided by CNN Money. The company reported a total revenue of $5.51 billion for the past year, which decreased by 11.41% compared to the previous year. However, the total revenue remained flat since the last quarter at $1.27 billion. In terms of net income, PTVE reported a net loss of $223.00 million for the past year, which represents a significant decrease of 170.13% compared to the previous year. Despite this decrease, the net income held flat since the last quarter at $21.00 million. Earnings per share (EPS) also experienced a decline for PTVE stock. The company reported an EPS of -$1.26 for the past year, which decreased by 171.4% compared to the previous year. Similarly, the EPS held flat since the last quarter at $0.11. Overall, the financial performance of PTVE stock on March 2, 2024, reflects a challenging year for the company, with decreases in total revenue, net income, and EPS compared to the previous year. However, the fact that these metrics held flat since the last quarter could indicate some stability in the company’s financial performance in the short term. Investors will likely keep a close eye on PTVE stock to see if the company can turn around its financial performance in the coming quarters.

Tags: PTVE
Elaine Mendonca

Elaine Mendonca

Related Posts

NFT projects
Breaking News

The Impact of TikToks Fate on USChina Relations and American Tech Giants

March 16, 2024
Businesses finance
Breaking News

Blackstone Strategic Credit 2027 Term Fund BGB Announces Monthly Dividend of 93 Cents per Share

March 15, 2024
Healthcare-sector
Breaking News

Analyzing Short Interest in Molina Healthcare Inc MOH

March 15, 2024
Next Post
The Rise of Strategic Partnerships in Life Sciences: Trends Shaping the Future of Healthcare Innovation

Rambus Stock Price Surges with Accelerated Share Repurchase Program

Finance_Capitalistic

Title Wolfe Research Analyst Initiates Coverage of Corteva with Outperform Rating and 67 Price Target

Analyst Optimistic about Eli Lilly Cos Promising Future

Recommended

Infineon Stock

Infineon’s Strategic Pivot Amid Rising Asian Competition in Power Semiconductors

3 weeks ago
Asbury Automotive Stock

Asbury Automotive’s Expansion Strategy Faces Market Skepticism

8 months ago
ePlus Stock

ePlus Stock: A Quiet Transformation Gains Momentum

7 months ago
Rimini Stock

Rimini Street Stock: Executive Sales Cloud Strong Growth Narrative

7 months ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Bloom Energy Broadcom Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Oracle Palantir PayPal Plug Power Realty Income Robinhood Rocket Lab USA Salesforce Strategy Synopsys Take-Two Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

Shadow Banks, Record Defaults, and the $1.8 Trillion Fracture

Orora’s Strategic Pivot: Shifting Glass Production from the Middle East to Mexico

Fermi’s Texas Power Gamble Faces Investor Exodus and Delays

iShares MSCI World ETF: Stability Anchored by a Handful of Tech Titans

Coinbase Faces a Volatility Trap as Trading Slumps and New Products Launch

Ams Osram’s Gold Problem Meets AI Optimism

Trending

ImmunityBio Stock
Analysis

ImmunityBio’s Record Revenue Meets Mounting Legal Pressure

by Jackson Burston
April 11, 2026
0

ImmunityBio's stock is navigating a volatile path, caught between explosive commercial growth for its bladder cancer drug...

Strategy Stock

Strategy’s Solitary Bitcoin Bet: A $14.5 Billion Paper Loss and Unwavering Conviction

April 11, 2026
BioNTech Stock

BioNTech’s Oncology Drive Gains Momentum with Key Data and Analyst Backing

April 11, 2026
Shadow Banks, Record Defaults, and the $1.8 Trillion Fracture

Shadow Banks, Record Defaults, and the $1.8 Trillion Fracture

April 11, 2026
Orora Stock

Orora’s Strategic Pivot: Shifting Glass Production from the Middle East to Mexico

April 10, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • ImmunityBio’s Record Revenue Meets Mounting Legal Pressure
  • Strategy’s Solitary Bitcoin Bet: A $14.5 Billion Paper Loss and Unwavering Conviction
  • BioNTech’s Oncology Drive Gains Momentum with Key Data and Analyst Backing

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com